1887

Journal of Medical Microbiology logo

Volume 44, Issue 1

Tuberculosis into the next century: Proceedings of a symposium held on 4 February 1995 at the Liverpool School of Tropical Medicine Free

Preview this article:
Preview Magnify

There is no abstract available.

  • Received:
  • Accepted:
  • Published Online:
© J. MED. MICROBIOL. 1996
Loading

Article metrics loading...

/content/journal/jmm/10.1099/00222615-44-1-1
1996-01-01
2024-04-20
Loading full text...

Full text loading...

/deliver/fulltext/jmm/44/1/medmicro-44-1-1.html?itemId=/content/journal/jmm/10.1099/00222615-44-1-1&mimeType=html&fmt=ahah

References

  1. Cave A. J. E. The evidence for the incidence of tuberculosis in ancient Egypt. Br J Tuberc 1939; 33:142–152
     [Google Scholar]
  2. Manchester K. Tuberculosis and leprosy in antiquity: an interpretation. Med Hist 1984; 28:162–173
     [Google Scholar]
  3. Formicola V., Milanesi Q., Scarsini C. Evidence of spinal tuberculosis at the beginning of the fourth millennium BC from Arene Candide Cave (Liguria, Italy). Am J Phys Anthropol 1987; 72:1–6
     [Google Scholar]
  4. Ritchie W. A. Paleopathological evidence suggesting pre-Columbian tuberculosis in New York State. Am J Phys Anthropol 1952; 10:305–317
     [Google Scholar]
  5. Pfeiffer S. Paleopathology in an Iroquoian ossuary with special reference to tuberculosis. Am J Phys Anthropol 1984; 65:181–189
     [Google Scholar]
  6. Stirland A., Waldron T. The earliest cases of tuberculosis in Britain. J Arch Sci 1990; 17:221–230
     [Google Scholar]
  7. Buchan W. Domestic Medicine or a treatise on the cure and prevention of diseases. Newcastle, UK: Mackenzie and Dent; 1813180–192
     [Google Scholar]
  8. Lowell A. M., Edwards L. B., Palmer C. E. Tuberculosis, vital and health statistics monographs. Cambridge, MA: American Harvard University Press; 1969
     [Google Scholar]
  9. Villemin J. A. Études sur la tuberculose. Paris: Ballière; 1868
     [Google Scholar]
  10. Koch R. Die aetiologie der tuberculose. Berliner Klinische Wochenschrift 1882; 19:221–230
     [Google Scholar]
  11. Koch R. The aetiology of tuberculosis (English translation). Rev Infect Dis 1982; 4:1270–1274
     [Google Scholar]
  12. Dubos R., Dubos J. The white plague: tuberculosis, man and society. Boston USA: Little Brown; 1952
     [Google Scholar]
  13. Paul H. Tuberculosis. The control of diseases Edinburgh: E and J Livingstone; 1964222–254
     [Google Scholar]
  14. Iseman M. D., Madsen L. A. Drug resistant tuberculosis. Clin Chest Med 1989; 10:341–353
     [Google Scholar]
  15. Nisar M., Narula M., Beeching N., Davies P. D. O. HIV related tuberculosis in England and Wales. Tubercle Lung Dis 1992; 73:200–202
     [Google Scholar]
  16. Hayward A. C., Watson J. M. Tuberculosis in England and Wales 1982–1993: notifications exceeded predictions. CDR Rev 1995; 3:R29–R33
     [Google Scholar]
  17. Spence D. P. S., Hotchkiss J., Williams C. S. D., Davies P. D. O. Tuberculosis and poverty. BMJ 1993; 307:759–761
     [Google Scholar]
  18. Davies P. D. O. Tuberculosis and migration. J R Coll Phys Lond 1995; 29:113–118
     [Google Scholar]
  19. Mangtani P., Jolley D. J., Watson J. M., Rodrigues L. C. Socioeconomic deprivation and notification rates for tuberculosis in London during 1982–91. BMJ 1995; 310:963–966
     [Google Scholar]
  20. Bhatti N., Law M. R., Morris J. K., Halliday R., Moore-Gillon J. Increasing incidence of tuberculosis in England and Wales: a study of likely causes. BMJ 1995; 310:967–969
     [Google Scholar]
  21. Watt B., Rayner A., Harris G. Modern methods in mycobacteriology. Rev Med Microbiol 1993; 4:97–105
     [Google Scholar]
  22. Mabilat C., Desvarenne S., Panteix G. Routine identification of Mycobacterium tuberculosis complex isolates by automated hybridization. J Clin Microbiol 1194; 32:2702–2705
     [Google Scholar]
  23. Hawkey P. M. The role of polymerase chain reaction in the diagnosis of mycobacterial infections. Rev Med Microbiol 1994; 5:21–32
     [Google Scholar]
  24. van Embden J. D. A., Cave M. D., Crawford J. T. Strain identification of Mycobacterium tuberculosis by DNA fingerprinting: recommendations for a standardized methodology. J Clin Microbiol 1993; 31:406–409
     [Google Scholar]
  25. Rogall T., Flohr T., Bottger E. C. Differentiation of Mycobacterium species by direct sequencing of amplified DNA. J Gen Microbiol 1990; 136:1915–1920
     [Google Scholar]
  26. Ross B. C., Dwyer B. Rapid, simple method for typing isolates of Mycobacterium tuberculosis by using the polymerase chain reaction. J Clin Microbiol 1993; 31:329–334
     [Google Scholar]
  27. Brisson-Noel A., Gicquel B., Lecossier D. Rapid diagnosis of tuberculosis by amplification of mycobacterial DNA in clinical samples. Lancet 1989; 4:1069–1071
     [Google Scholar]
  28. Pierre C., Lecossier D., Boussougant Y. Use of a reamplification protocol improves sensitivity of detection of Mycobacterium tuberculosis in clinical samples by amplification of DNA. J Clin Microbiol 1991; 29:712–717
     [Google Scholar]
  29. Thierry D., Cave M. D., Eisenach K. D. IS6110, an IS-like element of M. tuberculosis complex. Nucleic Acids Res 1990; 18:188
     [Google Scholar]
  30. Kolk A. H. J., Schuitema A. R. J., Kuijper S. Detection of Mycobacterium tuberculosis is clinical samples by using polymerase chain reaction and a nonradioactive detection system. J Clin Microbiol 1992; 30:2567–2575
     [Google Scholar]
  31. Shankar P., Manjunath N., Lakshmi R., Aditi B., Seth P., Shriniwas . Identification of Mycobacterium tuberculosis by polymerase chain reaction. Lancet 1990; 335:423
     [Google Scholar]
  32. Drobniewski F. A., Kent R. J., Stoker N. G., Uttley A. H. C. Molecular biology in the diagnosis and epidemiology of tuberculosis. J Hosp Infect 1994; 28:249–263
     [Google Scholar]
  33. Walker D. A., Taylor I. K., Mitchell D. M., Shaw R. J. Comparison of polymerase chain reaction amplification of two mycobacterial DNA sequences, IS6110 and the 65 kDa antigen gene, in the diagnosis of tuberculosis. Thorax 1992; 47:690–694
     [Google Scholar]
  34. de Lassence A., Lecossier D., Pierre C. Detection of mycobacterial DNA in pleural fluid from patients with tuberculous pleurisy by means of the polymerase chain reaction: comparison of two protocols. Thorax 1992; 47:265–269
     [Google Scholar]
  35. Telenti A., Imboden P., Marchesi F. Detection of rifampicin-resistance mutations in Mycobacterium tuberculosis . Lancet 1993; 341:647–650
     [Google Scholar]
  36. Buck G. E., O’Hara L. C., Summersgill J. T. Rapid, simple method for treating clinical specimens containing Mycobacterium tuberculosis to remove DNA for polymerase chain reaction. J Clin Microbiol 1992; 30:1331–1334
     [Google Scholar]
  37. Zwadyk P., Down J. A., Myers N., Dey M. S. Rendering of mycobacteria safe for molecular diagnostic studies and development of a lysis method for strand displacement amplification and PCR. J Clin Microbiol 1994; 32:2140–2146
     [Google Scholar]
  38. de Lamballerie X., Zandotti C., Vignoli C., Bollet C., de Micco P. A one-step microbial DNA extraction method using “Chelex 199” suitable for gene amplification. Res Microbiol 1992; 143:785–790
     [Google Scholar]
  39. Kolk A. H. J., Noordhoek G. T., de Leeuw O., Kuijper S., van Embden J. D. A. Mycobacterium smegmatis strain for detection of Mycobacterium tuberculosis by PCR used as internal control for inhibition of amplification and for quantification of bacteria. J Clin Microbiol 1994; 32:1354–1356
     [Google Scholar]
  40. Brisson-Noel A., Aznar C., Chureau C. Diagnosis of tuberculosis by DNA amplification in clinical practice evaluation. Lancet 1991; 338:364
     [Google Scholar]
  41. Eisenach K. D., Sifford M. D., Cave M. D. Detection of Mycobacterium tuberculosis in sputum samples using a polymerase chain reaction. Am Rev Respir Dis 1991; 144:1160–1163
     [Google Scholar]
  42. Kox L. F. F., Rhienthong D., Miranda A. M. A more reliable PCR for detection of Mycobacterium tuberculosis in clinical specimens. J Clin Microbiol 1994; 32:672–678
     [Google Scholar]
  43. Noordhoek G. T., Kolk A. H. J., Bjune G. Sensitivity and specificity of PCR for detection of Mycobacterium tuberculosis: a blind comparison study among seven laboratories. J Clin Microbiol 1994; 32:277–284
     [Google Scholar]
  44. Shinnick T. M., Jones V. Molecular approaches to the diagnosis of tuberculosis. In Bloom B. R. (ed) Tuberculosis: pathogenesis, protection and control Washington, DC: American Society for Microbiology; 1994; 32517–530
     [Google Scholar]
  45. Jones V., Alden M. J., Curry J. I. Detection and identification of Mycobacterium tuberculosis directly from sputum sediments by amplification of rRNA. J Clin Microbiol 1993; 31:2410–2416
     [Google Scholar]
  46. Miller N., Hernandez S. G., Cleary T. J. Evaluation of Gen-Probe amplified Mycobacterium tuberculosis direct test and PCR for direct detection of Mycobacterium tuberculosis in clinical specimens. J Clin Microbiol 1994; 32:393–397
     [Google Scholar]
  47. Pfyffer G. E., Kissling P., Wirth R., Weber R. Direct detection of Mycobacterium tuberculosis complex in respiratory specimens by a target-amplified test system. J Clin Microbiol 1994; 32:918–923
     [Google Scholar]
  48. Small P. M., van Embden J. D. A. Molecular epidemiology of tuberculosis. In Bloom B. R. (ed) Tuberculosis: pathogenesis, protection and control Washington, DC: American Society for Microbiology; 1994; 321542–1546
     [Google Scholar]
  49. McAdam R. A., Hermans P. W. M., van Soolingen D. Characterization of a Mycobacterium tuberculosis insertion sequence belonging to the IS3 family. Mol Microbiol 1990; 4:1607–1613
     [Google Scholar]
  50. Hermans P. W. M., van Soolingen D., Bik E. M., de Haas P. E. W., Dale J. W., van Embden J. D. A. The insertion element ISP987 from Mycobacterium bovis BCG is located in a hot spot integration region for insertion elements in M. tuberculosis complex strains. Infect Immun 1991; 59:2695–2705
     [Google Scholar]
  51. Collins D. M., Stephens D. M. Identification of insertion sequence, IS1081, in Mycobacterium bovis . FEMS Microbiol Lett 1991; 83:11–16
     [Google Scholar]
  52. van Soolingen D., Hermans P. W. M., de Haas P. E. W., van Embden J. D. A. Insertion element IS1081-associated restriction fragment length polymorphism in Mycobacterium tuberculosis complex species: a reliable tool for recognizing Mycobacterium bovis BCG. J Clin Microbiol 1992; 30:1772–1777
     [Google Scholar]
  53. Groenen P. M. A., Bunschoten A. E., van Soolingen D., van Embden J. D. A. Nature of DNA polymorphism in the direct repeat cluster of Mycobacterium tuberculosis; application for strain differentiation by a novel typing method. Mol Microbiol 1993; 10:1057–1065
     [Google Scholar]
  54. Hermans P. W. M., van Soolingen D., van Embden J. D. A. Characterization of a major polymorphic tandem repeat in Mycobacterium tuberculosis and its potential use in the epidemiology of Mycobacterium kansasii and Mycobacterium gordonae . J Bacteriol 1992; 174:4157–4165
     [Google Scholar]
  55. Wiid I. J. F., Werely C., Beyers N., Donald P., van Helden P. D. Oligonucleotide (GTG)5 as a marker for Mycobacterium tuberculosis strain identification. J Clin Microbiol 1994; 32:1318–1321
     [Google Scholar]
  56. van Soolingen D., de Haas P. E. W., Hermans P. W. M., Groenen P. M. A., van Embden J. D. A. Comparison of various repetitive DNA elements as genetic markers for strain differentiation and epidemiology of Mycobacterium tuberculosis . J Clin Microbiol 1993; 31:1987–1995
     [Google Scholar]
  57. van Soolingen D., de Haas P. E. W., Hermans P. W. M., van Embden J. D. A. DNA fingerprinting of Mycobacterium tuberculosis . In Clark V. L., Bavoil D. (eds) Methods in enzymology London: Academic Press; 1994; 235196–205
     [Google Scholar]
  58. Das S., Chan S. L., Allen B. W., Mitchison D. A., Lowrie D. B. Application of DNA fingerprinting with IS986 to sequential mycobacterial isolates obtained from pulmonary tuberculosis patients in Hong Kong before, during and after short-course chemotherapy. Tubercle Lung Dis 1993; 74:47–51
     [Google Scholar]
  59. van Soolingen D., Hermans P. W. M., de Haas P. E. W., Soil D. R., van Embden J. D. A. Occurrence and stability of insertion sequences in Mycobacterium tuberculosis complex strains: evaluation of an insertion sequence-dependent DNA polymorphism as a tool in the epidemiology of tuberculosis. J Clin Microbiol 1991; 29:2578–2586
     [Google Scholar]
  60. Cave M. D., Eisenach K. D., Templeton G. Stability of DNA fingerprint pattern produced with IS6110 in strains of Mycobacterium tuberculosis . J Clin Microbiol 1994; 32:262–266
     [Google Scholar]
  61. Daley C. L., Small P. M., Schecter G. F. An outbreak of tuberculosis with accelerated progression among persons infected with the human immunodeficiency virus: an analysis using restriction-fragment-length polymorphisms. N Engl J Med 1992; 326:231–235
     [Google Scholar]
  62. Coronado V. G., Beck-Sague C. M., Hutton M. D. Transmission of multidrug-resistant Mycobacterium tuberculosis among persons with human immunodeficiency virus infection in an urban hospital: epidemiologic and restriction fragment length polymorphism analysis. J Infect Dis 1993; 168:1052–1055
     [Google Scholar]
  63. Jereb J. A., Burwin K. R., Dooley S. W. Nosocomial outbreak of tuberculosis in a renal transplant unit: application of a new technique for restriction fragment length polymoiphism analysis of Mycobacterium tuberculosis isolates. J Infect Dis 1993; 168:1219–1224
     [Google Scholar]
  64. Yuen L. K. W., Ross B. C., Jackson K. M., Dwyer B. Characterization of Mycobacterium tuberculosis strains from Vietnamese patients by Southern blot hybridization. J Clin Microbiol 1993; 31:1615–1618
     [Google Scholar]
  65. Yang Z. H., de Haaz P. E. W., van Soolingen D., van Embden J. D. A., Andersen A. B. Restriction fragment length polymorphism of Mycobacterium tuberculosis strains isolated from Greenland during 1992: evidence of tuberculosis transmission between Greenland and Denmark. J Clin Microbiol 1994; 32:3018–3025
     [Google Scholar]
  66. Genewein A., Telenti A., Bemasconi C. Molecular approaches to identifying route of transmission of tuberculosis in the community. Lancet 1993; 342:841–844
     [Google Scholar]
  67. Godfrey-Faussett P., Stoker N. G. Aspects of tuberculosis in Africa. 3. Genetic ‘fingerprinting’ for clues to the pathogenesis of tuberculosis. Trans R Soc Trop Med Hyg 1992; 86:471–475
     [Google Scholar]
  68. Chevrel-Dellagi D., Abderrahman A., Haltiti R., Koubaji H., Gicquel B., Dellagi K. Large-scale DNA fingerprinting of Mycobacterium tuberculosis strains as a tool for epidemiological studies of tuberculosis. J Clin Microbiol 1993; 31:2446–2450
     [Google Scholar]
  69. Small P. M., McClenny N. B., Singh S. P., Schoolnik G. K., Tompkins L. S., Michelsen P. A. Molecular strain typing of Mycobacterium tuberculosis to confirm cross-contamination in the mycobacteriology laboratory and modification of procedures to minimize occurrence of false-positive cultures. J Clin Microbiol 1993; 31:1677–1682
     [Google Scholar]
  70. Collins D. M., Erasmuson S. K., Stephens D. M., Yates G. F., de Lisle G. W. DNA fingerprinting of Mycobacterium bovis strains by restriction fragment analysis and hybridization with insertion elements IS1081 and IS6110 . J Clin Microbiol 1993; 31:1143–1147
     [Google Scholar]
  71. Skuce R. A., Brittain D., Hughes M. S., Beck, L-A., Neill S. D. Genomic fingerprinting of Mycobacterium bovis from cattle by restriction fragment length polymorphism analysis. J Clin Microbiol 1994; 32:2387–2392
     [Google Scholar]
  72. Palittapongampim P., Chomyc S., Fanning A., Kunimoto D. DNA fragment length polymorphism analysis of Mycobacterium tuberculosis isolates by arbitrarily primed polymerase chain reaction. J Infect Dis 1993; 167:975–978
     [Google Scholar]
  73. Linton C. J., Jalal H., Leeming J. P., Millar M. R. Rapid discrimination of Mycobacterium tuberculosis strains by random amplified polymorphic DNA analysis. J Clin Microbiol 1994; 32:2169–2174
     [Google Scholar]
  74. Plikaytis B. B., Crawford J. T., Woodley W. Rapid, amplification-based fingerprinting of Mycobacterium tuberculosis . J Gen Microbiol 1993; 139:1537–1542
     [Google Scholar]
  75. Haas W. H., Butler W. R., Woodley C. L., Crawford J. T. Mixed-linker polymerase chain reaction: a new method for rapid fingerprinting of isolates of the Mycobacterium tuberculosis complex. J Clin Microbiol 1993; 31:1293–1298
     [Google Scholar]
  76. Palittapongampim P., Chomyc S., Fanning A., Kunimoto D. DNA fingerprinting of Mycobacterium tuberculosis isolates by ligation-mediated polymerase chain reaction. Nucleic Acids Res 1993; 21:761–762
     [Google Scholar]
  77. Goyal M., Young D., Zhang Y., Jenkins P. A., Shaw R. J. PCR amplification of variable sequence upstream of katG gene to subdivide strains of Mycobacterium tuberculosis complex. J Clin Microbiol 1994; 32:3070–3071
     [Google Scholar]
  78. Plikaytis B. B., Marden J. L., Crawford J. T., Woodley C. L., Butler W. R., Shinnick T. M. Multiplex PCR assay specific for multidrug-resistant strain W of Mycobacterium tuberculosis . J Clin Microbiol 1994; 32:1542–1546
     [Google Scholar]
  79. Bloom B. R., Murray C. J. L. Tuberculosis: commentary on a reemergent killer. Science 1992; 257:1055–1064
     [Google Scholar]
  80. Centres for Disease Control Nosocomial transmission of multidrug-resistant tuberculosis among HIV-infected persons - Florida and New York, 1988–1991. MMWR 1991; 40:585–591
     [Google Scholar]
  81. Zhang Y., Heym B., Allen B. The catalase-peroxidase gene and isoniazid resistance of Mycobacterium tuberculosis . Nature 1992; 358:591–593
     [Google Scholar]
  82. Baneijee A., Dubnau E., Quemard A. inhA, a gene encoding a target for isoniazid and ethionamide in Mycobacterium tuberculosis . Science 1994; 263:227–230
     [Google Scholar]
  83. Finken M., Kirschner P., Meier A. Molecular basis of streptomycin resistance in Mycobacterium tuberculosis′, alterations of the ribosomal protein S12 gene and point mutations within a functional 16S ribosomal RNA pseudoknot. Mol Microbiol 1993; 9:1239–1246
     [Google Scholar]
  84. Tarkiff H. E., Salazar L., Guerrero C. Cloning and nucleotide sequence of Mycobacterium tuberculosis gyrA and gyrB genes and detection of quinolone resistance mutations. Antimicrob Agents Chemother 1994; 38:773–780
     [Google Scholar]
  85. Heym B., Honore N., Truffot-Pemot C. Implications of multidrug resistance for the future of short-course chemotherapy of tuberculosis: a molecular study. Lancet 1994; 344:293–298
     [Google Scholar]
  86. Zhang Y., Young D. Molecular genetics of drug resistance in Mycobacterium tuberculosis . J Antimicrob Chemother 1994; 34:313–319
     [Google Scholar]
  87. Cole S. T. Mycobacterium tuberculosis: drug resistance mechanisms. Trends Microbiol 1994; 2:411–415
     [Google Scholar]
  88. Middlebrook G. Isoniazid resistance and catalase activity of tubercle bacilli. Am Rev Tuberc 1954; 69:471–472
     [Google Scholar]
  89. Winder F. G. Mode of action of the antimycobacterial agents and associated aspects of the molecular biology of the mycobacteria. In Ratledge C., Stanford J. (eds) The biology of the mycobacteria vol 1 London: Academic Press; 1982354–438
     [Google Scholar]
  90. Zhang Y., Garbe T., Young D. Transformation with katG restores isoniazid sensitivity in Mycobacterium tuberculosis isolates resistant to a range of drug concentrations. Mol Microbiol 1993; 8:521–524
     [Google Scholar]
  91. Benveniste R., Davies J. Mechanisms of antibiotic resistance in bacteria. Annu Rev Biochem 1973; 42:471–506
     [Google Scholar]
  92. Shoeb H. A., Bowman B. U., Ottolenghi A. C. Evidence for the generation of active oxygen by isoniazid treatment of extracts of Mycobacterium tuberculosis H37Ra. Antimicrob Agents Chemother 1985; 27:404–407
     [Google Scholar]
  93. Johnsson K., Schultz P. G. Mechanistic studies of the oxidation of isoniazid by the catalase-peroxidase from Mycobacterium tuberculosis . J Am Chem Soc 1994; 116:7425–7426
     [Google Scholar]
  94. Meissner G. The bacteriology of the tubercle bacilli. In Barry V. C. (ed) The chemotherapy of tuberculosis London: Butter-worths; 196465–110
     [Google Scholar]
  95. Styblo K., Sutherland I. Epidemiology of tuberculosis in children. Bull Int Union Tuberc 1982; 57:133–139
     [Google Scholar]
  96. Starke J. R., Jacobs R. F., Jereb J. Resurgence of tuberculosis in children. J Pediatr 1992; 120:839–855
     [Google Scholar]
  97. Miller F. J. W., Seale R. M. E., Taylor M. D. Tuberculosis in children. London: JA Churchill; 1963
     [Google Scholar]
  98. Smith M. H. D. Tuberculosis in adolescents. Clin Pediatr 1967; 6:9–15
     [Google Scholar]
  99. Nemir R. L. Perspectives in adolescent tuberculosis: three decades of experience. Pediatrics 1986; 78:399–405
     [Google Scholar]
  100. Centers for Disease Control Tuberculosis morbidity — United States, 1992. MMWR 1993; 42:696–704
     [Google Scholar]
  101. Centers for Disease Control Expanded tuberculosis surveillance and tuberculosis morbidity — United States, 1993. MMWR 1994; 43:361–366
     [Google Scholar]
  102. Medical Research Council Cardiothoracic Epidemiology Group Tuberculosis in children: a national survey of notifications in England and Wales in 1988. Arch Dis Child 1994; 70:497–500
     [Google Scholar]
  103. Ormerod L. P. Results of tuberculosis contact tracing: Blackburn 1982–90. Respir Med 1993; 87:127–131
     [Google Scholar]
  104. Goodyear H. M., Moore-Gillon J. C., Price E. H., Larcher V. F., Savage M. O., Wood C. B. S. Mycobacterial infection in an inner city children’s hospital. Arch Dis Child 1993; 69:229–231
     [Google Scholar]
  105. Delacourt C., Marie T. M., Bonnerot V. Computed tomography with normal chest radiographs in tuberculous infection. Arch Dis Child 1993; 69:430–432
     [Google Scholar]
  106. Dolin P. J., Raviglione M. C., Kochi A. Global tuberculosis incidence and mortality during 1990–2000. Bull World Health Organ 1994; 72:213–220
     [Google Scholar]
  107. Okot-Nwang M., Wabwire-Mangen F., Kagezi V. B. A. Increasing prevalence of tuberculosis among Mulago Hospital admissions, Kampala, Uganda (1985–89). Tubercle Lung Dis 1993; 74:121–125
     [Google Scholar]
  108. Luo C., Chintu C., Bhat G. Human immunodeficiency virus type-1 infection in Zambian children with tuberculosis: changing seroprevalence and evaluation of a thiacetazone-fiee regimen. Tubercle Lung Dis 1994; 75:110–115
     [Google Scholar]
  109. Dumois J. A. Tuberculosis in children with HIV infection. Pediatr AIDS HIV Infect: fetus adolescent 1992; 3:177–182
     [Google Scholar]
  110. Braun M. M., Cauthen G. Relationship of the human immunodeficiency virus epidemic to pediatric tuberculosis and Bacillus Calmette-Guerin immunisation. Pediatr Infect Dis J 1992; 11:220–227
     [Google Scholar]
  111. WHO Tuberculosis/HIV research. WHO/TUB/92.167
     [Google Scholar]
  112. Barnes P. F., Block A. B., Davidson P. T., Snider D. E. Tuberculosis in patients with human immunodeficiency virus infection. N Engl J Med 1991; 324:1644–1650
     [Google Scholar]
  113. Moss W. J., Dedyo T., Suarez M., Nicholas S. W., Abrams E. Tuberculosis in children infected with human immunodeficiency virus: a report of five cases. Pediatr Infect Dis J 1992; 11:114–120
     [Google Scholar]
  114. Jones D. S., Malecki J. M., Bigler W. J., Witte J. J., Oxtoby M. J. Pediatric tuberculosis and human immunodeficiency virus infection in Palm Beach County, Florida. Am J Dis Child 1992; 146:1166–1170
     [Google Scholar]
  115. Gutman L. T., Moye J., Zimmer B., Tian C. Tuberculosis in human immunodeficiency virus exposed or infected United States children. Pediatr Infect Dis J 1994; 13:963–968
     [Google Scholar]
  116. Muganga N., Nkuadiolandu A., Mashako L. M. N. Clinical manifestations of AIDS in children in Kinshasa. Pediatrie 1991; 46:825–829
     [Google Scholar]
  117. Lepage P., van de Perre P., Vliet G. V. Clinical and endocrinologic manifestations in perinatally human immunodeficiency virus type 1-infected children aged 5 years or older. Am J Dis Child 1991; 145:1248–1251
     [Google Scholar]
  118. Chintu C., Bhat G., Luo C. Seroprevalence of human immunodeficiency virus type 1-infection in Zambian children with tuberculosis. Pediatr Infect Dis J 1993; 12:499–504
     [Google Scholar]
  119. Sassan-Morokro M., De Cock H. M., Ackah A. Tuberculosis and HIV infection in children in Abidjan, Cote d’Ivoire. Trans R Soc Trop Med Hyg 1994; 88:178–181
     [Google Scholar]
  120. Chintu C., Luo C., Bhat G., Raviglione M., Du Pont H., Zumla A. Cutaneous hypersensitivity reactions due to thiacetazone in the treatment of tuberculosis in Zambian children infected with HIV-1. Arch Dis Child 1993; 68:665–668
     [Google Scholar]
  121. Hoyt L., Oleske J., Holland B., Connor E. Non tuberculous mycobacteria in children with acquired immunodeficiency syndrome. Pediatr Infect Dis J 1992; 11:354–360
     [Google Scholar]
  122. Rutstein R. M., Cobb P., McGowan K. L., Pinto-Maitin J., Starr S. E. Mycobacterium avium intracellulare complex infection in HIV-infected children. AIDS 1993; 7:507–512
     [Google Scholar]
  123. Shata A. M. A. Diagnosis of tuberculosis in children. Dissertation of Masters in Tropical Paediatrics Degree, Liverpool School of Tropical Medicine 1994
     [Google Scholar]
  124. Joint Tuberculosis Committee Chemotherapy and management of tuberculosis in the United Kingdom: recommendations of the Joint Tuberculosis Committee of the British Thoracic Society. Thorax 1990; 45:403–408
     [Google Scholar]
  125. Tuberculosis in Children Guidelines for diagnosis, prevention and treatment (a statement of the Scientific Committees of the IUATLD). Bull Int Union Tuberc Lung Dis 1991; 66:61–67
     [Google Scholar]
  126. Treatment of Tuberculosis Guidelines for National Programmes. Geneva: World Health Organization; 1993
     [Google Scholar]
  127. American Academy of Pediatrics Chemotherapy for tuberculosis in infants and children. Pediatrics 1992; 89:161–165
     [Google Scholar]
  128. Centers for Disease Control Guidelines for preventing the transmission of Mycobacterium tuberculosis in health-care facilities, 1994. MMWR 1994; 43:66
     [Google Scholar]
  129. Humphries M. The management of tuberculous meningitis. Thorax 1992; 47:577–581
     [Google Scholar]
  130. Dutt A. K., Moers D., Stead W. W. Short-course chemotherapy for extrapulmonary tuberculosis: nine years experience. Ann Int Med 1986; 104:7–12
     [Google Scholar]
  131. Alarcon F., Escalante L., Perez Y., Banda H., Chacon G., Duenas G. Tuberculous meningitis: short course of chemotherapy. Arch Neurol 1990; 47:1313–1317
     [Google Scholar]
  132. Jacobs R. F., Sunakom P., Chotpitayasunonah T., Pope S., Kelleher K. Intensive short course chemotherapy for tuberculosis meningitis. Pediatr Infect Dis J 1992; 11:194–197
     [Google Scholar]
  133. Palur R., Rajshekhar V., Chandy M. J., Joseph T., Abraham J. Shunt surgery for hydrocephalus in tuberculous meningitis: a long-term follow-up study. J Neurosurg 1991; 74:64–69
     [Google Scholar]
  134. Seth V., Beotra A., Bagga A., Seth S. Drug therapy in malnutrition. Ind J Pediatr 1992; 92:1341–1346
     [Google Scholar]
  135. Sudra P., Tan Dam G., Kochi A. Tuberculosis; a global overview of the situation. Bull World Health Organ 1992; 70:149–159
     [Google Scholar]
  136. Ormerod L. P. Respiratory tuberculosis. In Davies P. D. O. (ed) Clinical tuberculosis London: Chapman and Hall; 199473–92
     [Google Scholar]
  137. Humphries M. J., Lam W. K., Teah R. Non-respiratory tuberculosis. In Davies P. D. O. (ed) Clinical tuberculosis London: Chapman and Hall; 199493–104
     [Google Scholar]
  138. Hong Kong Chest Service/British Medical Research Council Controlled trial of 2, 4 and 6 months of pyrazinamide in 6 month, 3 times weekly regimens for smear positive pulmonary tuberculosis, including assessment of a combined preparation of isoniazid, rifampicin and pyrazinamide. Results at 30 months. Am Rev Respir Dis 1991; 143:700–706
     [Google Scholar]
  139. Villorina M. E., Geiter L. J., Simone P. M. The multidrug resistant tuberculosis challenge to public health efforts to control tuberculosis: 1992. Public Health Rep 1992; 107:616–625
     [Google Scholar]
  140. Nolte F. S., Metchock M., McGowan J. E. Direct detection of M. tuberculosis in sputum by polymerase chain reaction and DNA hybridization. J Clin Microbiol 1993; 31:1777–1782
     [Google Scholar]
  141. Godffey-Faussett P. DNA finger printing, a powerful tool for the study of tuberculosis. In Davies P. D. O. (ed) Clinical tuberculosis London: Chapman and Hall; 1994391–400
     [Google Scholar]
  142. Rieder H. L. Misbehaviour of a dying epidemic: a call for less speculation and better surveillance. Tubercle Lung Dis 1992; 73:181–183
     [Google Scholar]
  143. Hass D. W., Des Prez R. M. Tuberculosis and AIDS: a historical perspective on recent developments. Am J Med 1994; 96:439–450
     [Google Scholar]
  144. De Cock K. M., Soro B., Coulibaly I. M., Lucas S. B. Tuberculosis and HIV infection in sub-Saharan Africa. J Am Med Assoc 1992; 268:1581–1587
     [Google Scholar]
  145. Joint Tuberculosis Committee of the British Thoracic Society Guidelines on the management of tuberculosis and HIV infection in the United Kingdom. BMJ 1992; 304:1231–1233
     [Google Scholar]
  146. Selwyn P. A., Hartel D., Lewis V. A. A prospective study of the risk of tuberculosis among intravenous drug users with HIV infection. N Engl J Med 1989; 320:545–550
     [Google Scholar]
  147. Hamburg M. A., Frieden T. R. Tuberculosis transmission in the 1990s. N Engl J Med 1994; 330:1750–1751
     [Google Scholar]
  148. Alland D., Kalkut G. E., Moss A. R. Transmission of tuberculosis in New York city - an analysis by DNA fingerprinting and conventional epidemiologic methods. N Engl J Med 1994; 330:1710–1716
     [Google Scholar]
  149. Small P. M., Hopewell P. C., Singh S. P. The epidemiology of tuberculosis in San Francisco - a population based study using conventional and molecular methods. N Engl J Med 1994; 330:1703–1709
     [Google Scholar]
  150. Gilks C. F. Prophylaxis for HIV-associated infections in the developing world. J Antimicrob Chemother 1993; 31: Suppl B 119–128
     [Google Scholar]
  151. Shafer R. W., Chirgwin K. D., Glatt A. E. HIV prevalence, immunosuppression and drug resistance in patients with tuberculosis in an area endemic for AIDS. AIDS 1991; 5:399–405
     [Google Scholar]
  152. Gilks C. F., Brindle R. J., Mwachari C. Disseminated M. avium infection among HIV-infected patients in Kenya. J AIDS (in press)
    [Google Scholar]
  153. Batungwanayo J., Taelman H., Allen S. Pleural effusion, tuberculosis and HIV-1 infection in Kigali, Rwanda. AIDS 1993; 7:73–79
     [Google Scholar]
  154. Lucas S. B., De Cock K. M., Hounnou A. Contribution of tuberculosis to slim disease in Africa. BMJ 1994; 308:1531–1533
     [Google Scholar]
  155. Brindle R. J., Nunn P. P., Batchelor B. I. F. Infection and morbidity in patients with tuberculosis in Nairobi, Kenya. AIDS 1993; 7:1469–1474
     [Google Scholar]
  156. Nunn P., Kibuga D., Gathua S. Cutaneous hypersensitivity reactions due to thiacetazone in HIV-1 seropositive patients treated for tuberculosis. Lancet 1991; 377:627–630
     [Google Scholar]
  157. Okwera A., Whalen C., Byekwaso F. Randomised trial of thiacetazone and rifampicin-containing regimens for pulmonary tuberculosis in HIV-infected Ugandans. Lancet 1994; 344:1323–1328
     [Google Scholar]
  158. World Health Organization The HIV/AIDS and tuberculosis epidemics - implications for TB control. WHO Geneva 1994 document WHO/TB/CARG(4)/94.4
     [Google Scholar]
  159. Editorial The global challenge of tuberculosis. Lancet 1994; 344:277–278
     [Google Scholar]
  160. Hinshaw H. C., Feldman W. H. Streptomycin in treatment of clinical tuberculosis: a preliminary report. Proc Staff Meetings Mayo Clin 1945; 20:313–318
     [Google Scholar]
  161. Robitzek E. H., Selikoff I. J. Hydrazine derivatives of isonicotinic acid (Rimifan, Marsilid) in the treatment of active progressive caseous - pneumonic tuberculosis: a preliminary report. Am Rev Tuberc 1952; 65:402–428
     [Google Scholar]
  162. Medical Research Council Treatment of pulmonary tuberculosis with streptomycin and para-aminosalicylic acid. BMJ 1950; 2:1073–1085
     [Google Scholar]
  163. East African/British Medical Research Councils Controlled clinical trial of short course (6 months) regimens of chemotherapy for treatment of pulmonary tuberculosis. Lancet 1972; 1:1079–1085
     [Google Scholar]
  164. East African/British Medical Research Councils Controlled clinical trial of short course (6 month) regimens of chemotherapy for treatment of pulmonary tuberculosis (second report). Lancet 1973; 1:1331–1339
     [Google Scholar]
  165. East African/British Medical Research Councils Controlled clinical trial of short course (6 month) regimens of chemotherapy for treatment of pulmonary tuberculosis (third report). Lancet 1974; 2:237–240
     [Google Scholar]
  166. Mackaness G. B. The intracellular activation of pyrazinamide and nicotinamide. Am Rev Tuberc Pulmon Dis 1956; 74:718–728
     [Google Scholar]
  167. Dickinson J. M., Aber V. R., Mitchison D. A. Bactericidal activity of streptomycin, isoniazid, rifampicin, ethambutol and pyrazinamide alone and in combination against Mycobacterium tuberculosis . Am Rev Respir Dis 1977; 116:627–635
     [Google Scholar]
  168. Snider D. E., Graczyk J., Bek E., Rogowski J. Supervised six months treatment of newly diagnosed pulmonary tuberculosis using isoniazid, rifampicin and pyrazinamide with and without streptomycin. Am Rev Respir Dis 1984; 130:1091–1094
     [Google Scholar]
  169. Combs D. L., O’Brian R. J., Geiter L. J. USHPS tuberculosis short course chemotherapy trial 21: effectiveness, toxicity and acceptability. The report of final results. Ann Intern Med 1990; 112:397–406
     [Google Scholar]
  170. Hong Kong Chest Service/Tuberculosis Research Centre, Madras/British Medical Research Council A double blind placebo controlled clinical trial of three anti-tuberculosis chemoprophylaxis regimens in patients with silicosis in Hong Kong. Am Rev Respir Dis 1992; 145:36–41
     [Google Scholar]
  171. Inderlied C. B. Antimycobacterial agents: in vitro susceptibility testing, spectrums of activity, mechanisms of action and resistance and assays for activity in biological fluids. In Lorian V. (ed) Antibiotics in laboratory medicine New York: Williams and Wilkins; 1991134–197
     [Google Scholar]
  172. Takayama K., Qureshii N. Structure and synthesis of lipids. In Kubica G. P., Wayne L. G. (eds) The mycobacteria: a source book (part A) New York: Marcel Dekker; 1984
     [Google Scholar]
  173. Kruger-Thiemer E. Isonicotinic acid hypothesis of the antituberculous action of isoniazid. Am Rev Tuberc Pulmon Dis 1958; 77:364–367
     [Google Scholar]
  174. Krishamurti C. R. Isonicotinic hydrazide. In Corcoran J. W., Hahn F. F. (eds) Antibiotics: mechanism of action of antimicrobial and antitumour agents New York: Springer, Verlag; 1975623–652
     [Google Scholar]
  175. Poso H., Paulin L., Brander E. Specific inhibition of spermidine synthase from mycobacteria by ethambutol. Lancet 1983; 1:1418
     [Google Scholar]
  176. Takayama K., Kilbum N. Inhibitors of synthesis of arabinogalactan by ethambutol in Mycobacterium smegmatis . Antimicrob Agents Chemother 1989; 33:1493–1499
     [Google Scholar]
  177. Heifets L. B., Iseman M. D., Crowle A. J., Lindholm-Levy P. J. Pyrazinamide is not active in vitro against Mycobacterium avium complex. Am Rev Respir Dis 1986; 134:1287–1288
     [Google Scholar]
  178. Brickner S. J., Manninen P. R., Vlanowicz D. A. Synthesis and antibacterial activity of novel, multicyclic fused-ring oxazolidinones. 33rd Interscience Congress of Antimicrobial Agents and Chemotherapy 1993 New Orleans: Abstract No. 72
    [Google Scholar]
  179. Kilbum J., Glickman S., Brickner S. In vitro antimycobacterial activity of novel multicyclic, fused-ring oxazolidinones. 33rd Interscience Congress of Antimicrobial Agents and Chemotherapy 1993 New Orleans: Abstract No. 73
    [Google Scholar]
  180. Gangadharam P. R. J. Gangamicin, a potential antimycobacterial drug. 33rd Interscience Congress of Antimicrobial Agents and Chemotherapy 1993 New Orleans: Abstract No. 77
    [Google Scholar]
  181. Cremieux A., Chevalier J., Sharpies D. Antimicrobial activity of 9-acridinones and 9-thro-alkylacridines. New insight into the mechanism of action of these drugs. 33rd Interscience Congress of Antimicrobial Agents and Chemotherapy 1993 New Orleans: Abstract No. 78
    [Google Scholar]
  182. Deitz W. H., Cook T. M., Goss W. A. Mechanism of actions of nalidixic acid on Escherichia coli III conditions required for lethality. J Bacteriol 1966; 91:768–773
     [Google Scholar]
  183. Hopewell P., Cynamon M., Starke J., Iseman M., O’Brien R. Evaluation of new anti-infective drugs for the treatment and prevention of tuberculosis. Clin Infect Dis 1992; 15: Suppl 1282–295
     [Google Scholar]
  184. Inderlied C. B., Bermudez L. E., Barbara-Bumham L., Wu M., Young L. In vitro and macrophage activity of KRM 1648 against the Mycobacterium avium complex (MAC). 33rd Interscience Congress of Antimicrobial Agents and Chemotherapy 1993 New Orleans: Abstract No. 69
    [Google Scholar]
  185. Hosoe K., Konishi A., Mae T., Fujii K., Hadaka T., Ohashi T. Pharmacokinetics of KRM-1648, a new rifampicin derivative, in rats and dogs. 33rd Interscience Congress of Antimicrobial Agents and Chemotherapy 1993 New Orleans: Abstract No. 70
    [Google Scholar]
  186. Pharma Projects May 1994; J4A:a954–955
  187. Brogden R. N., Filton A. Rifampicin - a review of its antimicrobial activity, pharmacokinetic properties and therapeutic efficacy. Drugs 1994; 47:983–1009
     [Google Scholar]
  188. Dickinson J. M., Mitchison D. A. In vitro properties of rifampicin (MDL 47B) relevant to its use in intermittent chemotherapy of tuberculosis. Tubercle 1987; 68:113–118
     [Google Scholar]
  189. Dhople A. M. In vitro activity of 2′ 2′ bipyridyl analogues against Mycobacterium avium and Mycobacterium tuberculosis . 33rd Interscience Congress of Antimicrobial Agents and Chemotherapy 1993 New Orleans: Abstract No. 74
    [Google Scholar]
  190. Pharma projects May 1994; J4A:a953
  191. Pharma projects May 1994; J4A:a952
  192. Gay J. D., DeYoung D. R., Roberts G. D. In vitro activities of norfloxacin and ciprofloxacin against Mycobacterium tuberculosis, Mycobacterium avium complex, M. chelonei, M. fortuitum and M. kansasii . Antimicrob Agents Chemother 1984; 26:94–96
     [Google Scholar]
  193. Tomioka H., Saito H., Sato K. Comparative antimycobacterial activities of the newly synthesised quinolone AM-1155, sparfloxacin and ofloxacin. Antimicrob Agents Chemother 1993; 37:1259–1263
     [Google Scholar]
  194. Robbins M. J., Felmingham D., Gruneberg R. N. Comparative in-vitro activity of Cl-960 (PD 127,391), a new fluoroquinolone, against Mycobacterium tuberculosis, and Mycobacterium ‘avium-intracellulareʼ complex. 5th European Congress of Clinical Microbiology and Infectious Diseases 1991 Oslo: Abstract No. 1720
    [Google Scholar]
  195. Saito H., Tomioka H., Sato K. In vitro antimycobacterial activity of OPC-17116 a newly synthesised quinolone. 31st Interscience Congress on Antimicrobial Agents and Chemotherapy 1991 Chicago Abstract no. 1468
    [Google Scholar]
  196. Felmingham D., Robbens M. J., Ghosh G. In vitro studies with Du 6859a, a new fluroquinolone antimicrobial. 31st Interscience Congress on Antimicrobial Agents and Chemotherapy 1991 Chicago: Abstract no. 981
    [Google Scholar]
  197. Wise R. Comparative penetrations of selected fluoroquinolones into respiratory tract fluids and tissues. Am J Med 1991; 91:67s–70s
     [Google Scholar]
  198. Cartier M. B., Scorreaux B., Zereborgh P. Cellular uptake, localisation and activity of fluoroquinolones in uninfected and infected macrophages. J Antimicrob Chemother 1990; 26: Suppl B 27–39
     [Google Scholar]
  199. Piersimoni C., Morbiducci V., Bomigia S. In vitro activity of the new quinolone lomefloxacin against Mycobacterium tuberculosis . Am Rev Respir Dis 1992; 146:1445–1447
     [Google Scholar]
  200. Bergan T., Dalhoff A., Rohwedder R. Pharmacokinetics of ciprofloxacin. Infection 1988; 16: Suppl 1s3–sl3
     [Google Scholar]
  201. Chadwick M., Nicholson G., Gaya H. Brief report: combination chemotherapy with ciprofloxacin for infection with M. tuberculosis in mouse model. Am J Med 1989; 87: Suppl 5a35s–36s
     [Google Scholar]
  202. Anagnostopula U., Rapti A., Vagratzakis E., Marinis E., Kapetaneas S. Ciprofloxacin in pulmonary tuberculosis treatment. Am Rev Respir Dis 1990; 141:a436
     [Google Scholar]
  203. Kahana L., Spino M. Ciprofloxacin in patients with mycobacterial infections: experience in 15 patients. DICP: Ann Pharmacother 1991; 25:919–924
     [Google Scholar]
  204. Mohanty K. C., Dhamgaye T. M. Controlled trial of ciprofloxacin in short term chemotherapy for pulmonary tuberculosis. Chest 1993; 104:1194–1198
     [Google Scholar]
  205. Kennedy N., Fox R., Kisyombe G. M. Early bactericidal and sterilizing activities of ciprofloxacin in pulmonary tuberculosis. Am Rev Respir Dis 1993; 148:1547–1551
     [Google Scholar]
  206. Berlin O. G. W., Young L. S., Bruckner D. A. In vitro activity of six fluorinated quinolones against Mycobacterium tuberculosis . J Antimicrob Chemother 1987; 19:611–615
     [Google Scholar]
  207. Lode H., Hoffke G., Olschewski P. Pharmacokinetics of ofloxacin after parental and oral administration. Antimicrob Agents Chemother 1987; 31:1338–1342
     [Google Scholar]
  208. Heifets L. B., Lindholm-Levy P. J. Bacteristatic and bactericidal activity of ciprofloxacin and ofloxacin against Mycobacterium tuberculosis and Mycobacterium avium complex . Tubercle 1987; 68:267–276
     [Google Scholar]
  209. Truffot-Pemot C., Ji B., Grosset J. Activities of pefloxacin and ofloxacin against mycobacteria in vitro and mouse experiments. Tubercle 1991; 72:57–64
     [Google Scholar]
  210. Tsukamura M., Nakamura E., Yoshi S., Amano H. Therapeutic effect of a new antibacterial substance, ofloxacin (DL 8280) on pulmonary tuberculosis. Am Rev Respir Dis 1985; 131:352–356
     [Google Scholar]
  211. Davidson D. T., Le H. Q. Drug treatment of tuberculosis 1992. Drugs 1992; 43:651–673
     [Google Scholar]
  212. Cambau E., Sougakoff W., Besson M., Truffot-Pemot M., Grosset J., Jarlier V. Selection of gyrA mutant of Mycobacterium tuberculosis resistant to fluoroquinolones during treatment with ofloxacin. J Infect Dis 1994; 170:479–483
     [Google Scholar]
  213. Japanese Ministry of Health and Welfare “Sparfloxacin and photosensitivity”. Report No. 127 1994
  214. Parish H. J. A history of immunization. Edinburgh: E and S Livingstone; 196592–106
     [Google Scholar]
  215. Lugosi L. Theoretical and methodological aspects of BCG vaccine from the discovery of Calmette and Guerin to molecular biology. A review. Tubercle Lung Dis 1992; 73:252–261
     [Google Scholar]
  216. Hart P. D., Sunderland I. BCG and vole bacillus vaccines in the prevention of tuberculosis in adolescence and early adult life. BMJ 1977; 2:292–295
     [Google Scholar]
  217. Zhang Y., Wallace R. J., Mazurek G. H. Genetic differences between BCG substrains. Tubercle Lung Dis 1995; 76:43–50
     [Google Scholar]
  218. Lagranderie M., Ravisse P., Marchal G. BCG-induced protection in guinea-pigs vaccinated and challenged via the respiratory route. Tubercle Lung Dis 1993; 74:38–46
     [Google Scholar]
  219. Lotte A., ten Dam H. G., Henderson R. Second IUATLK study on complications induced by intradermal BCG-vaccination. Bull Int Union Tuberc 1988; 63:47–83
     [Google Scholar]
  220. Bloom B. R., Fine P. E. M. The BCG experience: implications for future vaccines against tuberculosis. In Bloom B. R. (ed) Tuberculosis: pathogenesis protection and control Washington, DC: American Society for Microbiology; 1994531–557
     [Google Scholar]
  221. Praveen K. N., Smikle M. F., Prabhakar P. Outbreak of Bacillus Calmette-Guerin-associated lymphadenitis and abscesses in Jamaican children. Pediatr Infect Dis J 1990; 9:890–893
     [Google Scholar]
  222. Romanus V., Svensson A., Hallander H. O. The impact of changing BCG coverage on tuberculosis incidence in Swedish-born children between 1969 and 1989. Tubercle Lung Dis 1992; 73:150–161
     [Google Scholar]
  223. Gonzalez B., Moreno S., Burdach R. Clinical presentation of Bacillus Calmette-Guerin infections in patient with immunodeficiency. Pediatr Infect Dis J 1989; 8:201–206
     [Google Scholar]
  224. Braun M. M., Cauthen G. Relationship of the human immunodeficiency vims epidemic to pediatric tuberculosis and Bacillus Calmette-Guerin immunization. Pediatr Infect Dis J 1992; 11:220–227
     [Google Scholar]
  225. Weltman A. C., Rose D. N. The safety of Bacille Calmette-Guérin vaccination in HIV infection and AIDS. AIDS 1993; 7:149–157
     [Google Scholar]
  226. Lallemont-Le Coeur S., Lallemont M., Chenier D. BCG immunization in infants bom to HIV-1 seropositive mothers. AIDS 1991; 5:195–199
     [Google Scholar]
  227. Centers for Disease Control BCG vaccination and pediatric HIV infection — Rwanda 1988–90. MMWR 1991; 40:833–835
     [Google Scholar]
  228. WHO Expanded progam on immunization: joint WHO/ UNICEF statement on immunization and AIDS. Wkly Epidemiol Rec 1987; 62:53–54
     [Google Scholar]
  229. Cox R. A., Downs M., Niemans R. E. Immunogenetic analyses of human tuberculosis. J Infect Dis 1988; 158:1302–1308
     [Google Scholar]
  230. Smith P. G., BCG vaccination. In: Davies P. D. O. (ed) Clinical tuberculosis London: Chapman and Hall; 1994297–310
     [Google Scholar]
  231. Tuberculosis Prevention Trial Trial of BCG vaccines in south India for tuberculosis prevention: first report. Bull World Health Organ 1979; 57:819–827
     [Google Scholar]
  232. Colditz G. A., Brewer T. F., Berkey C. S. Efficacy of BCG vaccine in the prevention of tuberculosis: meta-analysis of the published literature. JAMA 1994; 271:698–702
     [Google Scholar]
  233. Brewer T. F., Colditz G. A. Relationship between Bacille Calmette-Guerin (BCG) strains and the efficacy of BCG vaccine in the prevention of tuberculosis. Clin Infect Dis 1995; 20:126–135
     [Google Scholar]
  234. Styblo K. Overview and epidemiologic assessment of the current global tuberculosis situation with an emphasis on control in developing countries. Rev Infect Dis 1989; 11: Suppl 2S339–S346
     [Google Scholar]
  235. IUATLD Criteria for discontinuation of vaccination programmes using Bacille Calmette-Guerin (BCG) in countries with a low prevalence of tuberculosis. Tubercle Lung Dis 1994; 75:179–181
     [Google Scholar]
  236. Romanus V. Tuberculosis in Bacillus Calmette-Guérin-immunized and unimmunized children in Sweden: a ten year evaluation following the cessation of general Bacillus Calmette-Guérin immunization of the newborn in 1975. Pediatr Infect Dis J 1987; 6:272–280
     [Google Scholar]
  237. Tmka L., Dankova D., Sandova E. Six years’ experience with the discontinuation of BCG vaccination 1. Risk of tuberculosis infection and disease. Tubercle Lung Dis 1993; 74:167–172
     [Google Scholar]
  238. Tmka L., Dankova D., Sandova E. Six years’ experience with the discontinuation of BCG vaccination 2. Cost and benefit of mass BCG vaccination. Tubercle Lung Dis 1993; 74:288–292
     [Google Scholar]
  239. Tmka L., Danikova D., Sandova E. Six years’ experience with the discontinuation of BCG vaccination. 4. Protective effect of BCG vaccination against the Mycobacterium avium/intracellular complex. Tubercle Lung Dis 1994; 75:348–352
     [Google Scholar]
  240. Booy R., Hodgson S., Carpenter L. Efficacy of Haemophilus influenzae type b conjugate vaccine PRP-T. Lancet 1994; 344:362–366
     [Google Scholar]
  241. Springett V. H., Sutherland I. A re-examination of the variations of efficacy of BCG vaccination against tuberculosis in clinical trials. Tubercle Lung Dis 1994; 75:227–233
     [Google Scholar]
  242. Editorial New tuberculins. Lancet 1984; 1:199–200
     [Google Scholar]
  243. Editorial Bettering BCG. Lancet 1992; 339:40–41
     [Google Scholar]
  244. Koch R. An address on bacteriological research delivered before the International Medical Congress, held in Berlin, August 1890. BMJ 1890; 2:380–383
     [Google Scholar]
  245. Fowler W. C. A preliminary report on the treatment of tuberculosis with turtle vaccine. Tubercle 1930; 12:7–12
     [Google Scholar]
  246. MacAssey L., Saleeby G. W. (eds) Spahlinger contra tuberculosis 1908–1931. New York: John Bale, Sons and Danielsson Ltd; 1934
     [Google Scholar]
  247. Spahlinger H. Note on the treatment of tuberculosis. Lancet 1922; 1:5–8
     [Google Scholar]
  248. Grange J. M. The mystery of the mycobacterial persister. Tubercle Lung Dis 1992; 73:249–251
     [Google Scholar]
  249. Stanford J. L., Stanford C. A., Rook G. A. W., Grange J. M. Immunotherapy for tuberculosis — investigative and practical aspects. Clin Immunother 1994; 1:430–440
     [Google Scholar]
  250. Stanford J. L., Rook G. A., Bahr G. M. Mycobacterium vaccae in immunoprophylaxis and immunotherapy of leprosy and tuberculosis. Vaccine 1990; 8:525–530
     [Google Scholar]
  251. Brown J. A. K., Stone M. M., Sutherland I. BCG vaccination of children against leprosy in Uganda. BMJ 1966; 1:7–14
     [Google Scholar]
  252. Kardjito T., Beck J. S., Grange J. M., Stanford J. L. A comparison of the responsiveness to four new tuberculins among Indonesian patients with pulmonary tuberculosis and healthy subjects. Eur J Respir Dis 1986; 69:142–145
     [Google Scholar]
  253. Stanford J. L., Stanford C. A., Ghazi-Saidi K. Vaccination and skin test studies on the children of leprosy patients. Int J Leprosy 1989; 57:38–14
     [Google Scholar]
  254. Ganapati R., Revankar C. R., Lockwood D. N. A pilot study of three potential vaccines for leprosy in Bombay. Int J Leprosy 1989; 57:33–37
     [Google Scholar]
  255. Nye P. M., Price J. E., Revankar C. R., Rook G. A. W., Stanford J. L. The demonstration of two types of suppressor mechanism in leprosy patients and their contacts by quadruple skin testing with mycobacterial reagent mixtures. Lepr Rev 1983; 54:9–18
     [Google Scholar]
  256. Nye P. M., Stanford J. L., Rook G. A. W. Suppressor determinants of mycobacteria and their potential relevance to leprosy. Lepr Rev 1986; 57:147–157
     [Google Scholar]
  257. Pozniak A., Stanford J. L., Rook G. A. W., Johnson N. McI. A tentative introduction of immunotherapy into the treatment of tuberculosis. Bull Int Union Tuberc 1987; 62:39–40
     [Google Scholar]
  258. Bahr G. M., Shaaban M. A., Gabriel M. Improved immunotherapy for pulmonary tuberculosis with Mycobacterium vaccae . Tubercle 1990; 71:259–266
     [Google Scholar]
  259. Vicirca A., Dominino J., Valentini E., Hartopp R., Bottasso O. A. A pilot study of immunotherapy with M. vaccae against tuberculosis. Tubercle Lung Dis 1994; 75: Suppl 347–48
     [Google Scholar]
  260. Onyebujoh P., Abdulmumini T., Robinson S., Rook G. A. W., Stanford J. L. Immunotherapy for tuberculosis in African conditions. Respir Med 1995; 89:199–207
     [Google Scholar]
  261. Farid R., Etemadi A., Mehvar M., Stanford J. L., Dowlati Y., Velayati A. A. Mycobacterium vaccae immunotherapy in the treatment of multi-drug-resistant tuberculosis: a preliminary report. Iranian J Med Sci 1994; 19:37–39
     [Google Scholar]
  262. Stanford J. L., Onyebujoh P. C., Rook G. A., Grange J. M., Pozniak A. Old plague, new plague, and a treatment for both?. AIDS 1993; 7:1275–1277
     [Google Scholar]
  263. Bahr G. M., Sattar M. A., Stanford J. L. HLA-DR and tuberculin tests in rheumatoid arthritis and tuberculosis. Ann Rheum Dis 1989; 48:63–68
     [Google Scholar]
  264. Khoo S. H., Wilkins E. G. L., Fraser I., Stanford J. L. Lack of T-cell response to common mycobacterial antigens in HIV-infected individuals — consequence or a co-factor?. IX International Conference on AIDS, Berlin6–11 June 1993 Abstract No. PO-A24-0551
    [Google Scholar]
  265. Bottasso O. A., Ingledew N., Keni M. Cellular immune response to common mycobacterial antigens in subjects seropositive for Trypanosoma cruzi . Lancet 1994; 344:1540–1541
     [Google Scholar]
  266. Stanford J. L. The history and future of vaccination and immunotherapy for leprosy. Trop Geogr Med 1994; 46:93–107
     [Google Scholar]
  267. Kochi A. The global tuberculosis situation and the new control strategy of the World Health Organization. Tubercle 1991; 72:1–6
     [Google Scholar]
  268. Murray C. J. L., Styblo K., Rouillon A. Tuberculosis in developing countries: burden, intervention and cost. Bull Int Union Tuberc 1990; 65:6–24
     [Google Scholar]
  269. International Union Against Tuberculosis and Lung Disease Tuberculosis guide for high prevalence countries. 2nd edn Paris: IUATLD; 1993
     [Google Scholar]
  270. World Health Organization Managing tuberculosis at the district level. Geneva: WHO; 1993
     [Google Scholar]
  271. De Cock K. M. Screening for tuberculosis and HIV in resource-poor countries. Lancet 1995; 345:873–874
     [Google Scholar]
  272. Madico G., Gilman R. H., Checkley W. Community infection ratio as an indicator for tuberculosis control. Lancet 1995; 345:416–119
     [Google Scholar]
  273. FitzGerald J. M. The downside of isoniazid chemoprophylaxis. Lancet 1995; 345:404
     [Google Scholar]
  274. Tayler E. M. Montoux screening for tuberculosis. Lancet 1995; 345:930–931
     [Google Scholar]
  275. Gebre N., Karlsson U., Jonsson G. Improved microscopical diagnosis of pulmonary tuberculosis in developing countries. Trans R Soc Trop Med Hyg 1995; 89:191–193
     [Google Scholar]
  276. Parry C. M., Kamoto O., Harries A. D. The use of sputum induction for establishing a diagnosis in patients with suspected pulmonary tuberculosis in Malawi. Tubercle Lung Dis 1995; 76:72–76
     [Google Scholar]
  277. Murray C. J., De Jonghe E., Chum H. J., Nyangulu D. S., Salomao A., Styblo K. Cost effectiveness of chemotherapy for pulmonary tuberculosis in three sub-Saharan African countries. Lancet 1991; 338:1305–1308
     [Google Scholar]
  278. Sepkowitz K. A., Raffalli J., Riley L., Kiehn T. E., Armstrong D. Tuberculosis in the AIDS era. Clin Microbiol Rev 1995; 8:180–199
     [Google Scholar]
  279. Sepkowitz K. A. AIDS, tuberculosis and the health care worker. Clin Infect Dis 1995; 20:232–242
     [Google Scholar]
  280. Wilkinson D. High-compliance tuberculosis treatment programme in a rural community. Lancet 1994; 343:647–648
     [Google Scholar]
  281. Gangadharan P. R. J. Chemotherapy of tuberculosis under programme conditions with special relevance to India. Tubercle Lung Dis 1994; 75:241–244
     [Google Scholar]
  282. Chakraborty A. K. Drugs are not enough. Tubercle Lung Dis 1994; 75:316–317
     [Google Scholar]
  283. Uplekar M. W., Shepard D. S. Treatment of tuberculosis by private general practitioners in India. Tubercle 1991; 72:284–290
     [Google Scholar]
  284. Akhtar T., Imran M. Management of tuberculosis by practitioners of Peshawar. J Pak Med Assoc 1994; 44:280–282
     [Google Scholar]
  285. Solomon S., Anuradha S., Rajasekaran S. Trend of HIV infection in patients with pulmonary tuberculosis in South India. Tubercle Lung Dis 1995; 76:17–19
     [Google Scholar]
  286. Onozaki I., Shakya T. M. Feasibility study of a district tuberculosis control programme with an 8-month short-course chemotherapy regimen utilizing the integrated health service network under field conditions in Nepal. Tubercle Lung Dis 1995; 76:65–71
     [Google Scholar]
http://instance.metastore.ingenta.com/content/journal/jmm/10.1099/00222615-44-1-1
Loading
Tuberculosis into the next century: Proceedings of a symposium held on 4 February 1995 at the Liverpool School of Tropical Medicine
J. Med. Microbiol. 44, 1 (1996); https://doi.org/10.1099/00222615-44-1-1
/content/journal/jmm/10.1099/00222615-44-1-1
/content/journal/jmm/10.1099/00222615-44-1-1
Loading

Data & Media loading...

Most cited Most Cited RSS feed

This is a required field
Please enter a valid email address
Approval was a Success
Invalid data
An Error Occurred
Approval was partially successful, following selected items could not be processed due to error